Mylan N.V. has reached an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited’s thrombosis business in Europe for approximately $763 million, subject to customary closing conditions and European regulatory clearances. The transaction is expected to be immediately accretive to Mylan upon closing and is anticipated to be accretive to Viatris upon the completion of Mylan’s previously announced combination with Upjohn t...